Shaping the future of accessible Canadian biomanufacturing

Published
Oct. 2, 2024
Shaping the future of accessible Canadian biomanufacturing
Canada is making significant strides in enhancing its life sciences sector, focusing on building resilience and fostering innovation. As the country addresses both immediate and long-term health needs, new initiatives are emerging that balance public benefit with strategic planning. This approach is setting the stage for a stronger and more sustainable future, where collaboration and forward-thinking strategies play key roles in shaping the industry.

As the industry landscape transforms, leaders offer valuable perspectives on driving leadership and innovation. Céline Chabée, Partner at Pender & Howe, a Canadian and USA member of the Kestria Alliance/Partner at Kestria Canada & USA, invites executive leaders in the Life Sciences sector to share their journeys and insights. In a recent conversation, Céline engaged with Isabelle Caron, CEO of the Biologics Manufacturing Centre (BMC) Inc., not only to explore her leadership style but also to discuss her vision and how she has embraced the post-pandemic reality with a constructive and open mindset.  Isabelle Caron heads an organization with approximately 100 employees. She has demonstrated innovative and empowering leadership, particularly through her emphasis on public-private partnerships and her constructive approach to navigating current challenges.

What drew you to this opportunity with the Biologics Manufacturing Centre? How does this opportunity align with your values?

Several elements of the proposal captured my attention. First, the vision behind the project—the intention for Canada to have domestic manufacturing capabilities. This would allow us to have full control in case of an emergency. That's very innovative; not many countries have implemented such a vision, which I found particularly attractive.

The business model was also compelling. It's unique. While the goal is to have a pandemic-ready site, a bio-manufacturing facility is extremely expensive. Therefore, balancing profitability with a combined mission of pandemic readiness and contract manufacturing services presents an interesting and challenging mix, which I found appealing as well.

Additionally, the prospect of building a legacy for future generations, so they are better equipped to face potential health emergencies, resonated with me. It's incredibly valuable and meaningful for me to use my knowledge and experience to contribute to the future.

Could you share your vision for the BMC, especially regarding the legacy and impact a leader can have on the organization?

My vision for the BMC is to develop an entity that operates with a holistic approach and promotes sustainable growth beyond pandemic readiness, which is one of the mandates of the BMC. We offer Contract Manufacturing Services, and my goal is to leverage this to foster a dynamic, resilient and growing life sciences ecosystem in Canada. Currently, it is challenging for biotech companies to quickly access biomanufacturing capabilities, often requiring them to go outside Canada, to the U.S. or elsewhere. The idea is to make these resources accessible within Canada, enabling companies to accelerate their development pipelines and bring innovations to market faster. This accelerated innovation will also lead to better health solutions for Canadian citizens. Thus, the vision extends beyond the BMC itself and aims to create a collaborative ecosystem that will strengthen our position and make Canada more attractive to international investments and talent.

How does your organization, with its public interest mission, intend to achieve all of this?

This is indeed a very ambitious goal. We aim to achieve it by addressing gaps in the current life sciences ecosystem. As a not-for-profit organization, we are not focused on large-scale manufacturing or producing high-volume, blockbuster products, which, while profitable, do not align with our mission. Our decision-making process is guided by different business drivers, with community benefit being our top priority rather than profitability. We intend to focus on smaller niches and low-volume products, even those with uncertain futures. For example, we may produce a clinical batch for a specific client who is advancing their development pipeline.

While their clinical trial may succeed, it could also fail, and they may not return to us. Nonetheless, we are committed to offering our biomanufacturing capabilities to biotech companies in Canada and abroad, with the goal of creating value within Canada. By bringing activities back to Canada that are currently outsourced, we can contribute to the Canadian economy and foster the growth of the life sciences ecosystem.

Could you elaborate on the advantages of this holistic approach and whether Kestria’s support is recognized in advancing your mission?

In my opinion, the advantages of a holistic approach lie in the ability to create synergies and foster sustainable growth. Beyond pandemic readiness, these synergies help build a stronger ecosystem in Canada, allowing it to be more than just the sum of its individual parts. This approach ensures that the return on investments—whether from governmental bodies or the private sector—maximizes the benefits for the community.

Fostering ecosystem growth leads to the establishment of more companies, which in turn requires more qualified professionals. Talent acquisition and expanding the pool of skilled individuals are crucial to sustaining the growth of our ecosystem. As part of the BMC's role, I see our involvement in ensuring that the talent pool grows in parallel with the industry. This will enable us to build something truly sustainable, and Kestria, as a global alliance of executives, can definitely play a key role in this.

While we will see organic growth in Canada's talent pool, I believe we also need international talent to join the workforce, at least in the short term. Canada currently has a limited number of senior executives with valuable experience in the life sciences industry, likely due to the industry's stagnation over the past few decades. Bringing in an external pool of qualified executives will help maintain the existing ecosystem while we develop our national talent pool. However, it is currently very challenging to find highly qualified executives to fill the critical roles we are seeking. These roles are vital, as they define strategic directions and make difficult decisions for our companies.

About BMC

The Biologics Manufacturing Centre (BMC) Inc. in Montreal is a state-of-the-art GMP facility dedicated to the domestic production of vaccines and biologics in Canada. The center focuses on supporting public health by ensuring a reliable domestic supply of biologics, collaborating with industry and academia, and engaging in international and public interest projects. With a highly qualified workforce and a strong commitment to quality, BMC plays a crucial role in Canada's biomanufacturing infrastructure, offering technology transfer, drug substance production, analytical services, fill and finish services, secondary packaging and expert consulting services.

Stay Ahead with the Latest Industry Insights

Subscribe to our weekly newsletter designed for busy execs, entrepreneurs, and aspiring leaders.

Subscribe

We value your privacy

By selecting “Accept all”, you give your consent to our use of cookies. These cookies and data are essential for the smooth functioning of our website. For detailed information about the cookies we use, their purposes, and our partners, please click “Manage cookies”. Here, you can also customize your preferences, and modify or withdraw your consent at any time. Learn more